Quick Answer
Lexeo Therapeutics, Inc. reported Stockholders Equity of $246.67 million for fiscal year 2025.
Lexeo Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $246.67M | +111.1% |
| 2024 | $116.84M | +2.9% |
| 2023 | $113.53M | +200.5% |
| 2022 | -$112.95M | -103.1% |
| 2021 | -$55.60M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $120.83M | -13.3% | -12.6% |
| June 30, 2025 | $138.22M | -16.2% | +56.9% |
| March 31, 2025 | $88.11M | -51.8% | -24.6% |
| December 31, 2024 | $116.84M | +2.9% | -16.1% |
| September 30, 2024 | $139.33M | +185.6% | -15.5% |
| June 30, 2024 | $164.95M | +214.9% | -9.8% |
| March 31, 2024 | $182.95M | +239.5% | +61.1% |
| December 31, 2023 | $113.53M | +200.5% | +169.7% |
- Lexeo Therapeutics, Inc. showed an increase of +111.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, Lexeo Therapeutics, Inc.’s stockholders equity has grown by 543.6% (from -$55.60 million to $246.67 million).
- The most recent figure is from Lexeo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: